B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $7.91.
According to TipRanks, Mamtani is an analyst with an average return of -23.5% and a 21.96% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Madrigal Pharmaceuticals, and CymaBay Therapeutics.
Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $24.00.
See today’s best-performing stocks on TipRanks >>
NVAX market cap is currently $746.7M and has a P/E ratio of -1.09.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
- Novavax Stock (NASDAQ:NVAX) Has a Shot at Recovering
- PFE, MRNA: Vaccine Makers Get a Boost from FDA Nod
- Biotech Alert: Searches spiking for these stocks today
- Novavax call volume above normal and directionally bullish
- U.S. First Lady Tests Positive for COVID as Cases Spike — Is It Time to Jump Back Into Vaccine Stocks?
